SELLAS Life Sciences (SLS) Free Cash Flow (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Free Cash Flow data on file, last reported at -$8.8 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 2.98% year-over-year to -$8.8 million in Q1 2026; TTM through Mar 2026 was -$28.1 million, a 16.56% increase from a year earlier, with the FY2025 full-year figure at -$28.4 million, up 19.78% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$8.8 million, down from -$4.9 million in the prior quarter.
• Over the last five years, Free Cash Flow for SLS reached as high as -$4.8 million in Q4 2023 and fell as low as -$12.1 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$7.5 million across 5 years, with a median of -$7.2 million in 2024.
• Across the five-year window, Free Cash Flow slumped 69.61% in 2023 and jumped 31.05% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$5.2 million in 2022, then increased by 6.35% to -$4.8 million in 2023, then sank by 48.25% to -$7.2 million in 2024, then soared by 31.05% to -$4.9 million in 2025, then tumbled by 78.43% to -$8.8 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$8.8 million in Q1 2026, -$4.9 million in Q4 2025, and -$7.1 million in Q3 2025.